Biotech | April 06, 2022
Singlera Genomics announces research collaboration with Astellas Pharma
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)